0A-S1-1

 

CONGENITAL HEART DISEASE (CHD): MANAGEMENT IN THE NEXT MILLENNIUM

Park IS

Asian Medical Center, Univ. of Ulsan College of Medicine, Seoul, Korea

 

Approximately 70-80% of patients (pt) with CHD can now survive without sequela as a result of remarkable progress in treatment (Tx) of CHD. Catheter Tx is well established as an initial or supplementary Tx in various CHD. Now babies born with pulmonary atresia with intact ventricular septum, complete TGA and single ventricle (SV) have a better chance to survive with less sequela and fewer operations due to a combined and planned approach from echocardiographer, catheter interventionist and surgeon. Despite these progress, however, as much as 20-30% of pt either die or suffer from sequela even with state-of-the-art Tx. Unsettled problems include Eisenmenger reaction, complex tetralogy of Fallot with major aorto-pulmonary collaterals, truncus arteriosus, artificial valve, heterotaxy, pulmonary vein stenosis, elastin arteriopathy, congenitally corrected TGA, SV, and Fontan sequela. To improve outcome, we need to change health care delivery system by developing standards for practice, national or regional data registry with outcome disclosure, and centralizing the care, as well as improving technical aspect in Tx. Finally, educating primary care physicians and trainees to facilitate case recognition at an earlier age is probably one of the most important endeavor to improve final outcome for these children.